Phase 1/2 Study to Evaluate The Safety and Pharmacokinetics of Palbociclib (Ibrance?) in Combination With Irinotecan And Temozolomide or in Combination With Topotecan and Cyclophosphamide in Pediatric Patients With Recurrent or Refractory Solid Tumor

Details
Locations
Childrens Hospital Colorado
Principal Investigator

Margaret Macy, MD
Study ID
Protocol Number: 19-0299
More information available at ClinicalTrials.gov: NCT03709680
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers